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Background: To quantify the incremental cost associated with right ventricular failure (RVF) after left ventricular assist device (LVAD) placement.
Methods: Data on HeartMate XVE (n=107) and HeartMate II (n=58) LVAD recipients from 1/1/03-1/1/09 at our institution were retrospectively 
reviewed. Total hospital costs were adjusted to post-op costs using multivariable regression and stratified by billing category (Table 1). Clinical 
outcomes included: development of post-op RVF, need for RVAD, ICU length of stay (LOS), and in-hospital mortality.
Results: Among all LVAD recipients, 28.5% (n=47) were diagnosed with post-op RVF, and of these 42.6% (n=20) required an RVAD. RVF was 
associated with a mean $89,955 ± 34,279 higher post-op cost of hospitalization (p=0.01). The increased cost of RVF was driven by an increase in 
mean direct ($71,375 ± 21,012; p=0.001) versus indirect ($23,007 ± 21,413; p=0.284) costs. RVF requiring insertion of an RVAD was associated 
with a $273,619 ± 34,359 higher post-op cost of hospitalization (p<0.0001), and RVF was associated with a mean 7.8 ± 2.8 day longer ICU LOS 
(p=0.007). Although there was a trend toward increased in-hospital mortality among RVF (23.4%, n=11) versus non-RVF patients (11.9%, n=14), the 
difference did not achieve statistical significance (p=0.09).
Conclusions: RVF after LVAD placement is associated with a significant increase in post-operative costs. Efforts aimed at predicting and 
preventing RVF have the potential for significant cost-savings. 
Table 1: Incremental mean post-op costs associated with RVF by select billing categories
Billing category 
Mean difference in cost ($)
(Cost RVF - Cost non-RVF)
p-value
Blood bank 4,819 ± 2,550 0.061
Cardiac imaging 324 ± 149 0.031
Cardiac cath lab 3,992 ± 1,660 0.018
Diagnostic lab 3,726 ± 1,732 0.033
Boarding and nursing 26,300 ± 16,139 0.105
Operating room 7,343 ± 8,756 0.403
Pharmacy 14,226 ± 7,673 0.066
Radiology 1,161 ± 1,145 0.312
Respiratory care 4,815 ± 2,009 0.018
